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Apoptosis deregulation might have a role in the pathophysiology of polycythemia vera (PV). This study 
evaluated Bcl-2 molecule expression in CD34+ cells and leukocytes in 12 PV patients. Gene expression 
was investigated by real time PCR using SybrGreen Quantitect kit and protein expression was evaluated 
by western-blotting. JAK2 V617F mutation was detected according to Baxter et al (2005). CD34+ cells 
from PV patients presented higher levels of A1 and Mcl-1 expression (median: 22.6 and 5.2, respectively) 
in comparison with controls (0.9 and 0.5, p=0.004 and p=0.020); while Bcl-2 and Bcl-xL expression 
decreased in PV patients (0.18 and 1.19) compared with controls (1.39 and 2.01, p=0.006 and p=0.020). 
CD34+ cells in PV patients showed an elevated Bid expression (14.4) in comparison with healthy subjects 
(1.0; p=0.002). Patients’ leukocytes showed an A1 augmentation (7.41, p=0.001) and a reduced expression 
of Bax (0.19; p=0.040) and Bad (0.2; p=0.030). There was no correlation between JAK2 V617F allele 
burden and molecular expression. PV patients showed alterations in Bcl-2 members’ expression, which 
may interfere with control of apoptotic machinery and contribute to disease pathogenesis.
Uniterms: Polycythemia vera. Gene mutation. Gene expression. Apoptosis. Bcl-2 family members.
A desregulação da apoptose parece participar da fisiopatologia da policitemia vera (PV). Este estudo 
avaliou a expressão das moléculas da família Bcl-2 em células hematopoéticas CD34 + e leucócitos de 
12 pacientes com PV. Foram realizados: a quantificação da expressão gênica por PCR em tempo real 
utilizando kit Sybrgreen Quantitect, avaliação da expressão de proteínas por western-blot e detecção da 
mutação JAK2 V617F segundo Baxter et al. (2005). Células CD34 + dos pacientes com PV apresentaram 
maior expressão de A1 e Mcl-1 (mediana: 22,6 e 5,2, respectivamente) em comparação com controles 
(0,9 e 0,5, p = 0,004 e p = 0,020) e expressão de Bcl-2 e Bcl-xL diminuída nestes pacientes (0,18 e 1,19) 
em relação aos controles (1,39 e 2,01, p = 0,006 e p = 0,020). Células CD34 + dos pacientes com PV 
mostraram expressão elevada de bid (14,4) em comparação aos controles (1,0; p = 0,002). Leucócitos 
dos pacientes mostraram aumento de A1 (7,41, p = 0,001) e expressão reduzida do Bax (0,19; p = 0,04) 
e Bad (0,2; p = 0,030). Não houve correlação entre percentagem de alelos JAK2 V617F mutados e 
expressão molecular. Pacientes com PV apresentaram alterações na expressão de moléculas Bcl-2 que 
podem interferir no controle da apoptose e contribuir para a patogênese da doença.
Unitermos: Policitemia vera. Mutação gênica. Expressão gênica. Apoptose. Membros da Família Bcl-2. 
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INTRODUCTION
The 2001 WHO classification considered that the 
major myeloproliferative disorders (MPDs) are: chronic 
myelogenous leukemia (CML), polycythemia vera (PV), 
essential thrombocythemia (ET), and idiopathic myelo-
fibrosis (IMF). The discovery of a mutation in the Janus 
kinase led to an understanding of the pathogenesis of the 
classic MPDs. In 2008 the WHO classification revisions 
reorganized the MPDs into myeloproliferative neoplasms 
(MPNs) (Tefferi, Vardinam, 2008; Wadleigh, Tefferi, 
2010).
Polycythemia vera is a clonal disorder arising in a 
multipotent hematopoietic progenitor cell, exhibiting ac-
cumulation of normal red and white cells, platelets, and 
their progenitors in the absence of a definable stimulus. 
The hallmark of PV is the trilineage hematopoietic cell 
hyperplasia, but erythrocytosis is its most remarkable 
clinical manifestation (Spivak, 2002). According the 
2008 WHO guidelines, the major PV diagnostic criteria 
are: hemoglobin levels > 18.5 g/dL in men, 16.5 g/dL in 
women or other evidence of increased red cell volume and 
presence of the Janus kinase 2 mutation (JAK2 V617F), 
or other functionally similar mutation such as JAK2 exon 
12 mutation. The minor PV diagnostic criteria are: bone 
marrow biopsy showing hypercellularity with trilineage 
myeloproliferation; serum erythropoietin (EPO) level 
below the normal reference range; in vitro endogenous ery-
throid colony (EEC) formation. Diagnosis de PV requires 
meeting either both major criteria and one minor criterion 
or the first major criterion and two minor criteria (Tefferi, 
Vardinam, 2008; Wadleigh, Tefferi, 2010).
The JAK2 V617F somatic mutation has been detect-
ed in 95% of PV patients and in 40 to 60% of ET or IMF 
patients. It is responsible for the activation of downstream 
target genes of JAK/STAT pathways, which seem to be 
linked to cell apoptosis impairment. Furthermore, there 
are indications that there may be an association between 
the mutation status, PV pathogenesis, and prognosis. The 
JAK2 V617F homozygous mutation could promote the 
development of a polycythemic phenotype, since homo-
zygosis for the JAK2 mutation occurs in roughly 30% of 
patients with PV (Baxter et al., 2005; James et al., 2005; 
Kralovics et al., 2005; Levine et al., 2005; Levine et al., 
2007). 
Notwithstanding the new knowledge about PV and 
the description of new prognostic and diagnostic mark-
ers, the etiology and pathogenesis of this disease remains 
unclear. The mechanisms involved in PV molecular basis 
are still elusive. It seems that PV is a myeloaccumulative 
disorder rather than a myeloproliferative disorder (Spivak, 
2002). In this context, we postulate that apoptosis deregu-
lation may have a role in its pathophysiology.
Apoptosis could be triggered by mitochondrial 
(intrinsic) and death receptor (extrinsic) pathways. In the 
intrinsic pathway, cytochrome c is released upon stimula-
tion by a variety of cell-death triggers such as ultra violet 
light, cellular stress, chemotherapy, virus infection, cyto-
kine deprivation, and DNA damage. Cytochrome c release, 
in turn, leads to activation of Apaf-1 (apoptosis protease 
activating factor-1), caspase-9, and caspase-3 (Borner, 
2005; Jin; El Deiry, 2005; Yan, Shi, 2005).
The extrinsic apoptotic pathway involves the inter-
action of death receptors such as Fas and caspase-8, which 
lead to caspase-3 activation and cell death by apoptosis 
(Fulda; Debatin, 2006). Cell apoptotic machinery is mainly 
regulated by Bcl-2 family members (Borner, 2005), proba-
bly acting through the control of mitochondrial membrane 
permeability. Bcl-2 members could be divided in pro- (Bid, 
Bik, Bim, Bmf, Bok, Puma, Noxa, Bak, Bad, and Bax) 
and anti- apoptotic (A1, Bcl-2, Bcl-xL, Mcl-1, and Bcl-w) 
molecules (Borner, 2005; Sharper, Arnoult, Youle, 2004). 
The association between PV pathogenesis and 
apoptosis has been poorly investigated but its role in 
other myeloproliferative diseases was well established. 
The A1 protein seems to have an important role in the 
pathogenesis in several B-cell malignancies and acute 
leukemias (Simpson et al., 2006; Brien et al., 2007). The 
literature reports the association of the overexpression 
of the Mcl-1 antiapoptotic molecule with solid tumors, 
chronic lymphocytic leukemia, and chronic myeloid leu-
kemia pathogenesis and with resistance to chemotherapy 
(Kitada, Reed, 2004). Economopoulos et al. (2008) 
described an increase in A1 and Mcl-1 mRNA levels in 
blastic cells of myelodysplastic syndrome patients. Del 
Poeta et al. (2008) reported an increase in the expression 
of Bcl-2, Bcl-xL and Mcl-1 in acute myeloid leukemia. 
Zhang et al. (2004) showed that CD34+ cells from ET 
patients presented a high expression of Bcl-xL in the 
initial differentiation phase of megakaryocytes induced 
by thrombopoietin.
Zeuner et al. (2006) reported that PV patients had 
abnormal erythropoiesis, EPO independence or hyper-
sensitivity, and c-Flip overexpression, which could have 
contributed to apoptosis resistance and erythropoiesis 
alteration in some patients with the disease. Garçon et 
al. (2006) observed that only a sustained level of Bcl-xL 
is capable of giving rise to Epo-independent erythroid 
colony formation suggesting that, in PV patients, JAK2 
V617F may induce EEC via the STAT5/Bcl-xL pathway; 
the JAK2/STAT5/Bcl-xL pathway seems to be crucial to 
erythropoiesis and implicated in cell proliferation and 
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TABLE I - Demographic features, hematological parameters, and JAK2 V617F allele burden from PV patients
Patient Age Sex Skin 
Color
Hb 
(g/dL)
Ht 
(%)
WBC 
(/uL)
Plt (x109/L) JAK2 Allele 
Burden (%)
1 50 F B 19.1 57.9 8.08 207 Negative
2 66 F W 20.1 60 5.20 247 13
3 80 F W 15.9 44.5 8.80 541 90
4 54 F B 25.0 65 5.10 169 13
5 59 M W 19.7 60.2 20.00 568 87
6 59 M W 15.6 46.6 8.75 330 25
7 55 F W 22.4 66.8 7.47 276 52
8 61 F B 18.7 61.1 9.04 412 50
9 69 F W 18.1 57.3 6.35 255 40
10 84 F W 16.0 53.9 21.30 420 94
11 52 M W 17.4 53.5 5.50 229 Negative
12 72 F W 17.9 56 8.85 299 55
Abbreviations: PV, polycythemia vera; M, male; F, female, Hb, hemoglobin; Ht, hematocrit; WBC, white blood cell count; Plt, 
platelets; W, white; B, black.
survival. Deregulated erythropoiesis in PV involves EPO 
hypersensitivity and apoptosis resistance of erythroid 
precursor cells associated with abnormally increased acti-
vation of RAS-ERK and phosphoinositide-3 kinase-AKT 
pathways (Laubach et al., 2009).
These literature observations are leading investi-
gators to focus on studies to understand how cell death 
deregulation is relevant to the neoplasm’s pathophysiol-
ogy and to develop more effective therapeutic strategies. 
Therefore, the objective of this study was to investigate the 
expression of genes and proteins of Bcl-2 family members 
in CD34+ hematopoietic stem cells and leukocytes in PV 
patients and healthy subjects. The potential correlation 
between gene and protein expression with JAK2 muta-
tion allele burden and lymphocyte resistance to apoptosis 
is also analyzed.
SUBJECTS AND METHODS
Patients and controls
Twelve PV patients, not treated, were evaluated 
in this study and included only when PV diagnosis was 
confirmed according to the 2008 WHO criteria. Their 
demographic and clinical-laboratorial parameters are de-
scribed in Table I. The patients’ mean age was 63.4 years 
old (range 50-84 years). Three males and nine females 
were included in the study.
Peripheral blood samples were provided by healthy 
subjects recruited at the Faculty of Pharmaceutical 
Sciences, University of São Paulo (USP) at Ribeirão 
Preto. Marrow donors were obtained at the Bone Marrow 
Transplantation Unit of the University Hospital, Faculty 
of Medicine of Ribeirão Preto-USP. The samples were 
collected from 19 healthy subjects, whose mean age was 
38.4 years old (range 14-54 years), 12 males and 7 females. 
Leukocytes were obtained from 14 healthy individuals, 
5 males and 9 females, whose mean age was 54.4 years 
(range 41-80 years). The local ethics committee approved 
the study and all samples were collected after the subjects 
signed the Informed Consent Form.
Peripheral blood mononuclear cell and leukocyte 
separation
Peripheral blood mononuclear cells (PBMC) 
were isolated by the Ficoll-Hypaque method (His-
topaque®-1077, Sigma, St. Louis, Missouri, USA) accord-
ing to instructions by the manufacturer and as described 
by Boyum (1976).
Peripheral blood leukocytes were obtained from pa-
tients and controls using Haes-Steril® reagent (Voluven®, 
Frasenius Kabi, Campinas, Brazil). Briefly, the peripheral 
blood is mixed to Haes reagent in a 3:1 proportion, the 
mixture is decanted for 120 minutes at room temperature 
and leukocytes are recovered from the supernatant by 
centrifugation at 1800xg for 15 minutes. The cells were 
resuspended in PBS-ACD buffer (1mL) for counting and 
viability determinations with 0.4% Trypan Blue (Sigma-
Aldrich Chemie, Steinheim, Germany).
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CD34+ hematopoietic stem cell isolation
Bone marrow mononuclear cells were separated 
by Ficoll-Hypaque centrifugation (Histopaque®-1077, 
Sigma, St. Louis, MO, USA) and CD34+ hematopoietic 
stem cells (HSC) were obtained by positive selection us-
ing an immunomagnetic column according to the manu-
facturer’s protocol (MACS, Milteny Biotec, Bergisch 
Gladbach, Germany). 
After selection, the purity of CD34+ HSC was veri-
fied by flow cytometry. CD34+ HSC population’s purity 
was more than 91.80% in bone marrow transplantation 
donors and 87.06% in PV patients. 
SDS-PAGE and western-blot analysis
Peripheral leukocytes (2x109cel/L) from 4 healthy 
individuals and 4 PV patients were chosen to represent and 
investigate the results obtained by gene expression. The 
samples were chosen because we have more leukocyte 
aliquots from them than the others patients and because 
according to gene expression results they present a gene 
expression close to the median value of the evaluated mol-
ecule, which were washed once in ice-cold PBS, lysed di-
rectly in SDS-sample buffer (50 mM Tris-HCl, pH 6.8, 2% 
SDS, 10% glycerol, 2.5% b-mercaptoethanol) and boiled 
for 5 min. Samples were resolved under reducing condi-
tions for two hours at 80 volts in SDS-polyacrylamide gels. 
Separated proteins then were blotted onto polyvinylidene 
difluoride (PVDF) membranes (Pierce, Rockford, IL, 
USA) at 500 mA for two hours. Blots were blocked over-
night in TBST buffer (10 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 0.05% Tween) containing 0.1% sodium azide and 
5% non fat dried milk and then probed during two hours 
or overnight with an appropriate dilution of A1 polyclonal 
antibody (Santa Cruz, Santa Cruz, California, USA), Bad 
monoclonal antibody (PharmingenTM BD Biosciences, 
San Diego, California, USA), Bcl-xL polyclonal antibody 
(Biotechnology.Inc Santa Cruz, California, USA), and 
Bim polyclonal antibody (PharmingenTM BD Biosci-
ences). Proteins reactions to primary antibody were sec-
ondary antibody conjugated to horseradish peroxidase 
(GE Amersham, Arlington, IL, USA) using enhanced 
chemiluminescence (GE Amersham). A semi-quantitative 
assessment of protein expression was performed by band 
relative densities detection using the Alphaease software 
(Alpha Inotech, San Leandro, California, USA). Protein 
expressions were normalized by b-actin (Sigma-Aldrich, 
St. Louis, Missouri, USA) or β-tubulin (Sigma-Aldrich) 
endogenous expression. The densitometry methodology 
was applied to quantify the proteins, which were expressed 
by integrated density value (IDV). The protein expression 
results are presented as supplementary data.
Total RNA extraction, cDNA synthesis and real 
time PCR
Leukocyte and CD34+ HSC total RNAs were obtained 
according to the Trizol® protocol. RNA concentration and 
purity was determined by measuring fluorescence at 260 nm 
and 280 nm. One microgram of RNA was used for cDNA 
synthesis by High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, CA, USA), according 
to manufacturer instructions. Real time PCR assay was car-
ried out in cDNA to determine proapoptotic (Bad, Bak, Bax, 
Bid, Bik, Bim-EL, and Bok) and antiapoptotic gene expression 
(Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1) using SybrGreen PCR 
Master Mix Kit (Applied Biosystems), specific primers 
(Table II), and ABIPrism 7700 (Applied Byosytems). Βeta-
actin gene was used as housekeeping genes and the results 
were given as 2-∆∆Ct. Beta-actin was chosen as a housekeep-
ing gene because its expression is high in hematopoietic 
cells and it has a minimal expression variability between 
the samples evaluated in this study. 
JAK2/V617F mutation detection and allele burden 
calculation
The JAK2 V617F mutation was detected by real 
time PCR according to Baxter et al. (2005) and the results 
were presented as negative or allele burden of JAK2 posi-
tive mutation. 
Apoptosis resistance assay
Mononuclear cells from patients and controls were 
cultured with 2mg/mL of phytohemagglutinin (Sigma, 
St. Louis, MO, USA) in complete RPMI 1640 medium 
(Sigma) supplemented with 10% bovine fetal serum, 
10mM HEPES, 2mM L-glutamine, 100units/mL of peni-
cillin and 100ug/mL streptomycin, at 37 ºC in a 5% CO2 
during three days. 
Then, the mononuclear cells were treated with apop-
tosis inducers such as: actinomycin (ACT, 1 and 5 mM, 
Sigma-Aldrich), cycloheximide (CHX, 25 and 50 mM, 
Sigma-Aldrich), cytarabine (ARA-C, 25mM, Pfizer®, 
Milan, Italy), etoposide (VP-16, 25mM, Bristol-Meyers-
Squibb®, Mayaquez, Porto Rico), teniposide (VM-26, 
25 mM, Bristol-Meyers-Squibb®), staurosporine (STS, 1 
and 5 mM, Sigma-Aldrich) for twelve hours.
After incubation, mononuclear cells were recov-
ered from the culture medium by centrifugation (240x g, 
Deregulated expression of A1, Bcl-2, Bcl-xL, and Mcl-1 antiapoptotic proteins and Bid, Bad, and Bax proapoptotic genes 877
TABLE II - Primers sequences, amplicon size and their specific annealing temperature for quantitative real-time PCR
Genes 5’→ 3’ sequence Amplicon (bp) AT (ºC)
Bax F: CCC TTT TGC TTC AGG GTT TC
R: TCT TCT TCC AGA TGG TGA GTG
500 56
Bad F: CCG AGT GAG CAG GAA GAC TC
R: GGT AGG AGC TGT GGC GAC T
205 60
Bak F: TTT TCC GCA GCT ACG TTT TT
R: TGG TGG CAA TCT TGG TGA AGT
249 60
Bid F: GCT TCC AGT GTA GAC GGA GC
R: GTG CAG ATT CAT GTG TGG ATG
203 62
Bik F: TCT GCA ATT GTC ACC GGT TA
R: TTG AGC ACA CCT GCT CCT C
193 60
Bok F: TTT TCC GCA GCT ACG TTT TT
R: TGG TGG CAA TCT TGG TGA AGT
249 59
BimeL F: TCT GCA ATT GTC ACC GGT TA
R: AAG ATG AAA AGC GGG GCT CT
196 59
Bcl-2 F: ACG AGT GGG ATG GGG GAG ATG TG
R: GCG GTA GCG GCG GGA GAA GTC
204 67
Bcl-w F: AGT TCG AGA CCC GCT TCC
R: CCC GTC CCC GTA TAG AGC
308 60
Bcl-xL F: CTG AAT CGG AGA TGG AGA CC
R: TGG GAT GTC AGG TCA CTG AA
211 60
A1 F: GGC TGG CTC AGG ACT ATC
R: CCA GTT AAT GAT GCC GTC
227 50
Mcl-1 F: AGA AAG CTG CAT CGA ACC AT
R: CC AGC TCC TAC TCC AGC AAC
183 56
Noxa F: AGC TGG AAG TCG AGT GTG CT
R: ACG TGC ACC TCC TGA GAA AA
167 54
Puma F: GGA GCA GCA CCT GGA GTC
R: TA CTG TGC GTT GAG GTC GTC
156 60
β-actin F: GCC CTG AGG CAC TCT TCC A
R: CCA GGG CAG TGA TCT CCT TCT
192 58
Abbreviations: AT: annealing temperature; bp: base pair; F: forward; R: reverse.
10 minutes, 4 ºC), washed once with annexin buffer (10 mM 
HEPES pH 7.4; 150 mM NaCl; 5 mM KCl; 1 mM MgCl2; 
1,8 mM CaCl2) and incubated for 20 minutes with 100 mL 
of Annexin-V FITC. Subsequently, ten thousand cells 
were acquired with 40 mL of a propidium iodide solution 
(50 mg/mL) and the data were analyzed by the DIVA soft-
ware in a FACSCanto Flow Cytometer (Becton & Dickin-
son, San Jose, CA, USA). The results were expressed as 
percentage of apoptotic cells labeled with Annexin-V-FITC.
Statistical analysis
The Mann Whitney U-test was used to determine 
statistical differences in gene expression and protein 
expression between controls and PV patients. The Spear-
man’s correlation test was carried out to detect the associa-
tions of JAK2 V617F allele burden and gene expression, 
JAK2 V617F allele burden and percentage of apoptotic 
mononuclear cells, and gene expression and percentage of 
apoptotic mononuclear cells. The results were considered 
statistically significant when p values were < 0.05.
RESULTS
Gene expression of Bcl-2 family members in 
hematopoietic stem cells and peripheral leukocytes
CD34+ HSC from PV patients presented higher 
levels of A1 and Mcl-1 expression (median: 22.6 and 5.2, 
respectively) in comparison with controls (median: 0.9 
and 0.5, p=0.002 and p=0.008) (Figure 1; Supplementary 
Table S1). Bcl-2, Bcl-xL, Bax and Bad gene expressions 
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were decreased in PV patients CD34+ HSC (0.18, 1.19, 
6.76, 0.24) compared with controls (1.39, 2.01, 10.5 and 
4.42; p=0.006, p=0.020, p=0.010 and p=0.010) (Figures 1 
and 2). CD34+ HSC of PV patients showed increased Bid 
expression (14.4) in relation to normal individuals (1.0; 
p=0.002) (Figure 2; Supplementary Table S1). 
In contrast to controls (median A1=1.02, Bax=1.25 
and Bad=1.18), patient leukocytes showed an augmented 
A1 gene expression (7.41, p=0.001) (Figure 1) and a re-
duced expression of Bax (0.19; p=0.020) and Bad (0.2; 
p=0.030) (Figure 2). No significant differences between 
controls and PV patients were verified regarding expres-
sion of genes Bcl-w (Figure 1), Bik, Bim-EL, Bok, Noxa, 
and Puma (data not shown). 
FIGURE 1 - Antiapoptotic genes expressed in CD34+ HSC and leukocytes from PV patients and controls. Βeta-actin gene was 
used as endogenous control. The genes relative expression were detected by real time PCR and results were given as 2-∆∆Ct. The 
horizontal lines represent the median of gene expression in each group analyzed. A1 and Mcl-1 are overexpressed (median: 22.6 
and 5.2, respectively) in CD34+ HSC from PV patients in comparison with controls (median: 0.9 and 0.5, p=0.002 and p=0.008). 
Bcl-2 and Bcl-xL mRNA levels were decreased in PV patients’ CD34+ HSC (0.18 and 1.19) in relation to controls (1.39 and 2.01; 
p=0.006 and p=0.020). Patients’ leukocytes also showed an A1 gene expression augmentation (7.41, p=0.001). There were no 
statistically significant differences in mRNA levels of Bcl-2, Bcl-xL and Mcl-1 in patient leukocytes. No significant differences in 
Bcl-w expression between controls and PV patient CD34+ HSC and leukocytes were detected (p > 0.05).
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Bad, Bim-EL, Bcl-xL and A1 protein expression in 
peripheral leukocytes
Bad, BimEL, Bcl-xL and A1 protein expressions 
(Online Supplementary Figure S1) detected in peripheral 
leukocyte lysates from four healthy individuals and four 
PV patients were taken to represent the expression of these 
molecules in the whole group of patients and controls. 
Patient’s samples were randomly chosen to support and 
check gene expression results.
We chose samples with gene expression values 
similar to median of Bad, BimEL, Bcl-xL and A1. Evalua-
tion of protein expressions was performed to confirm gene 
expression data. The results showed high Bcl-xL and A1 
expression and low levels of Bad protein in PV patients in 
comparison to controls. Bim-EL expression was performed 
just because it is known that this molecule is susceptible to 
post-transcriptional regulation mechanisms. Bim-EL proteic 
FIGURE 2 - mRNA levels of Bid, Bax and Bad proapoptotic molecules in CD34+ HSC and leukocytes from PV patients and controls. 
Βeta-actin gene was used as endogenous control. Gene relative expressions were detected by real time PCR and results were given 
as 2-∆∆Ct. The horizontal lines represent the median of gene expression in each group analyzed. PV patients’ CD34+ HSC showed 
Bid elevated expression (median=14.4, p=0.002) in relation to normal individuals. The Bax (median= 6.76, p=0.010) and Bad 
(0.24, p=0.010) expression were reduced in patients’ CD34+ HSC. The Bad (0.2; p=0.030) and Bax (0.19; p=0.020) levels were 
also decreased in PV patient leukocytes compared with controls.
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levels were also reduced in patients, PV leukocytes having 
only 35% of Bim-EL normal values. Bad protein expression 
was significantly lower in PV patients in relation to controls, 
which were 60% higher. PV patients had triple Bcl-xL ex-
pression compared with control leukocytes. Hence, Bcl-xL 
and Bim-EL protein expression are different; they were op-
posite from that observed in PV gene expression profiles, 
whereas A1 and Bad data supported the mRNA level results. 
JAK2 V617F mutation allele burden did not 
correlate with gene expression of Bcl-2 family 
members
No correlation was detected between JAK2 V617F 
allele burden and antiapoptotic protein (A1, Bcl-2, Bcl-w, 
Bcl-xL, and Mcl-1) or proapoptotic gene expression (Bad, 
Bak, Bax, Bid, Bik, Bim-EL, and Bok) in CD34+ HSC or 
leukocytes (Supplementary Table S2).
Mononuclear cells from PV patients were 
resistant to apoptosis
Concerning assessment of mononuclear cell apop-
tosis, PV patients cells were more resistant to ACT-D 
1µM (median = 29.95; p=0.015), CHX 25mM and 50 mM 
(median = 5.53 and 19.80; p=0.002 and 0.001), STS 1 µM 
(median = 6.59; p<0.001), ARA-C 25µM (median = 2.76; 
p<0.001), VM26 25 µM (median = 22.80; p<0.003) and 
VP16 25 µM (median = 12.25; p<0.001) than controls 
(median = 39.70) (Figure 3). 
JAK2 mutation allele burden is not associated 
with the percentage of mononuclear cells 
apoptosis in PV patients
No significant correlation between the percentage of 
JAK2 V617F allele burden and mononuclear cell apoptosis 
FIGURE 3 - Percentage of mononuclear cell apoptosis induced by drugs in the PV and control groups. Patient’s mononuclear cells 
were more resistant to ACT-D 1 µM (p=0.015), CHX 25 mM and 50 mM (p=0.002 and 0.001), STS 1 µM (p<0.001), cytarabine 
25 µM (p<0.001), teniposide 25 µM (p<0.003), and etoposide 25 µM (p<0.001) than controls’ mononuclear cells.
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induced by STS, CHX, ACT-D, ARA-C, VP16 and VM26 
(data not shown) was found in PV patients.
Gene expression of Bcl-2 family members 
is linked to mononuclear cells’ resistance to 
apoptosis in PV patients
A negative correlation was detected between the per-
centage of PV cells apoptosis induced by ACT-D (1uM), 
CHX (50 mM) and ARA-C (25 µM) and A1 mRNA levels 
(r=-6527, p=0.044); r=-0. 527; p=0.033 and r=-0.900; 
p=0.041, respectively); ACT (5 mM), STS (1 mM) and 
CHX (50 mM) and Bcl-2 (r=-0.857; p=0.012; r=-0.691; 
p=0.038 and r=-0.9; p=0.040, respectively); ARA-C and 
Mcl-1 (r=-0.728, p=0.015). Another interesting result was 
that Bad expression was positively correlated with cell 
percentage of apoptosis induced by VM26 (r=0.7857; 
p=0.024). Thus, low levels of Bad gene are related to a 
decrease in cell apoptosis percentage mediated by VM26. 
These results indicate that death resistance to apop-
togenic inducers in PV patients is linked to A1, Mcl-1 and 
Bcl-2 antiapoptotic protein and Bad proapoptotic genes 
levels.
DISCUSSION
Several studies have addressed the clinical and 
laboratorial features in chronic MPDs these diseases, but 
the cellular and molecular mechanisms involved in the 
pathogenesis of MPD cells are still unclear.
Altered apoptosis regulation seems to contribute to 
the physiopathology of several diseases like neoplasia, 
autoimmune disorders, neurodegenerative disorders, my-
elodysplastic syndromes, and acute and chronic leukemia 
(Del Poeta et al., 2008; Economopoulou et al., 2008; Yan, 
Shi, 2005). The association of apoptosis-related proteins 
deregulation with PV pathogenesis, examined in the pres-
ent study, has been scarcely explored elsewhere.
A differential profile of Bcl-2 family members’ genes 
expression was verified in PV patients in relation to controls. 
Data suggest disequilibrium in anti- and proapoptotic gene 
expressions related to the intrinsic pathway, which is repre-
sented by a significant increase in A1 and Mcl-1 expression 
in marrow stem cells and A1 in peripheral blood and by a 
reduction in mRNA levels of Bad and Bax molecules. In ad-
dition, the low expression of these proapoptotic molecules is 
related to drug-induced mononuclear cells resistance, such 
as topoisomerase inhibitors, cytarabine, and cycloheximide. 
Furthermore, our results indicate a potential augmented 
survival in CD34+ HSC and peripheral leukocytes, leading 
to promoted clonal expansion and perpetuation of myeloid 
lineage cells characteristic of the disease.
The literature shows that inhibition of apoptosis by 
A1 and Mcl-1 genes may occur through inactivation of 
the Bak protein. Conformational change of Bak and mito-
chondrial MOMP formation are prevented by the A1 and 
Mcl-1 molecules, blocking release of cytochrome C and 
other apoptogenic factors, not activating caspase-3 and 
suppressing apoptosis (Chipuk, Green, 2008; Thomadaki, 
Scorilas, 2006). It is possible to speculate that the patients 
included in the present study showed cell resistance to 
apoptosis through this mechanism, as stem cells or leuko-
cytes showed elevation of A1 and Mcl-1 and decrease of 
Bad, Bim-EL and Bax in comparison with controls.
Another finding is related only to the increase in the 
Bcl-xL protein (supplementary data), a potent antiapoptotic 
molecule, which may contribute to a phenotype with a 
higher survival and myeloaccumulation of myeloid cells in 
PV patients. The findings in this investigation also include 
decreased levels of Bcl-2 and increased Bid, a paradox, 
since these molecules promote apoptosis potentiating and 
not blocking. It is possible that these molecules do not play 
a relevant role in the physiopathology of PV.
In addition, since apoptosis unleashing is dependent 
on the interaction and equilibrium of several proteins of 
the Bcl-2 family (Chipuk; Green, 2008), the increase of 
A1, Mcl-1, and Bcl-xL antiapoptotic molecules and the 
decreased expression of Bax and Bad would be sufficient 
to prevent cellular death in PV.
 A1 protein is abundantly expressed in bone marrow 
cells, spleen, and lung in several lineages originating in 
thymus, testicle, and intestine cancers (Thomadaki; Sco-
rilas, 2006). It has an important role in high risk leukemia 
and other B cell malignancies. This molecule is a direct 
target in the transcription of NF-kb, which is involved 
in myeloid and lymphoid differentiation, in apoptosis 
resistance by different stimuli, like the activation of death 
receptors (Simpson et al., 2006; Brien et al., 2007). 
Mcl-1 protein probably participates in the immune 
system development and hematopoiesis. In hematopoi-
etic cells the protein is regulated by ERK, JAK/STAT, 
p38, MAPK, P13K/AKT signaling and phosphorylation 
of elf2a and E2F1 and may be phosphorylated by JNK, 
GSK-3a/b, a cyclin-dependent kinase (Inoue et al., 2008). 
It may be inactivated and/or degraded by a caspase medi-
ated cleavage or other proteins (ubiquitin-proteasome 
pathway) (Wuillème-Toumi et al., 2006). In chronic my-
eloid leukemia (Aichberger et al., 2005), expression of 
Mcl-1 protein is frequently associated with resistance to 
chemotherapy and disease progression. In multiple my-
eloma (MM), chemoresistance is also caused by apoptosis 
deregulated pathways, with over expression of Mcl-1 and 
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an insignificant expression of Bcl-2 (Wuillème-Toumi 
et al., 2005). Increase in Mcl-1 levels is correlated with 
disease severity, turning the molecule into a potential 
therapeutic target in MM.
Mcl-1 protein neutralizes the proapoptotic func-
tion of Bim and prevents activation of death receptors 
(Wuillème-Toumi et al., 2006). Regulating the Mcl-1 
expression is important to break the Bim/Mcl-1 complex 
and induce Bim activation in HMCL-human myeloma 
and Hek-293-human embryonic kidney cell lines. It has 
been shown recently that Bim, a direct activator of Bax/
Bak, protects the mitochondrial membrane permeability 
dependent on the pair of proteins by loosing its activity 
(Chipuk, Green, 2008). Thus, increased levels of this 
protein interfere with mitochondrial membrane perme-
ability and activation of apoptosis extrinsic pathway, both 
contributing to the resistance profile to apoptosis shown 
by PV patient cells. 
The results in this study suggest that A1 and Mcl-1 
contribute to apoptosis resistance by means of direct or 
indirect Bax inhibition, by blocking the activation of Bad, 
tBax or Bim molecules and/or compromising the activation 
equilibrium of other proapoptotic proteins such as Bok and 
Noxa, which inhibit cytochrome liberation and caspase 3 
activation and suppress the apoptotic cascade.
Increased amounts of Bcl-xL protein in PV patients’ 
leukocytes confirm the data in the literature. Bcl-xL protein 
is increased in erythroid precursors and provokes cell ac-
cumulation in PV (Silva et al., 1998). Other reports con-
sider the molecule as the most potent antiapoptotic agent, 
its high levels being partially responsible for cell apoptosis 
resistance in patients with chronic myeloid leukemia 
(CML). It seems that Bcl-xL instead of Bcl-2 mediates the 
most prominent antiapoptotic effect of Bcr-abl tyrosine 
kinase in CML patients. Amarante-Mendes et al. (1998) 
showed that treatment with antisense oligonucleotides tar-
geted to Bcl-xL downregulates the expression of Bcl-x and 
increases Bcr-Abl positive cell susceptibility to apoptosis 
induced by staurosporine in CML.
The sensitive profile of PV mononuclear cells to 
several apoptogenic drugs (actinomycin D, staurosporine, 
cycloheximide, cytarabine, etoposide, and teniposide) was 
also evaluated in this research. Substances with diverse 
mechanisms of action were employed to induce cell death, 
aiming to analyze cell apoptotic machinery at a functional 
level and its relation to the expression profile of molecules 
of the Bcl-2 family members.
Our results suggest that PV patients’ mononuclear 
cells resistance to cell death is related to alterations in 
the gene expression profile of the molecules regulating 
apoptosis intrinsic pathway.
The percentage of JAK2 mutated alleles reflects the 
tumoral load in the disease and is linked to worse prognosis 
(Passamonti, Rumi, 2009; Finazzi, Barbui, 2008; Gangat 
et al., 2008; Vannucchi et al., 2007). Lack of correlation 
between the JAK2 (V617F) mutation and the genes in the 
study does not exclude the relation between the expression 
of these genes to the activity of JAK2-mutated tyrosine 
kinase or the presence of different mutations in JAK2 or 
other kinases. It is worth emphasizing that in the present 
study we only evaluated the JAK2 V617F mutation in the 
exon 14 in PV patients, we did not measure JAK2 activity 
or detect other mutations associated with PV pathogenesis, 
such as MPL or JAK2 mutation in the exon 12 (Vainchen-
ker, W. et al., 2011).
Nussenzveig et al. (2007) showed that events related 
to the JAK2 V617F mutation may not give rise to PV, 
but identification of the genetic lesion is essential to the 
development of therapeutic strategies, since inhibitors 
of active, constitutive tyrosine kinase JAK2 are not suf-
ficient to eradicate the disease. The authors correlated the 
frequency of the JAK2/V617F mutant allele with clonal-
ity and presence of endogenous erythroid colonies with 
allele homozygosis and demonstrated that PV is not only 
provoked by the mutation, which seems to be a second-
ary genetic event. However, the primary molecular lesion 
responsible for the clonal hematopoiesis was not defined.
JAK2 inhibitors have been explored as the most ef-
ficient therapeutic agents in MPDs but some patients do 
not respond to therapy and some are JAK2 negative. Thus, 
the importance of describing new therapeutic targets, as 
inserted in this context, for Bcl-2 family members. 
Apoptosis resistance to stimuli by drugs such as ac-
tinomycin D, cycloheximide, cytarabine, teniposide, and 
staurosporine correlates with high levels of A1, Mcl-1 and 
low expression of Bad and Bax.
Actinomycin D acts inhibiting the synthesis of RNA 
and it seems to potentiate Fas-mediated apoptosis, prevent 
binding of NF-kb to DNA (Wang et al., 2007), decrease 
the expression of the extrinsic antiapoptotic pathway, 
c-Flip, and stimulate Puma and Noxa expression of p53 
and APAF-1 pathway (Kalousek et al. , 2007). ACT-D and 
cycloheximide conduct cells to apoptosis via the TRAIL 
protein or TNF-a receptor. Both drugs are able to reduce 
RIP expression, a kinase having a death domain involved 
in TNF-R1 signaling that mediates NF-kb activation, 
which, in turn, may be antiapoptotic. They also reduce 
XIAP expression, a member of the IAP family responsible 
for the regulation of the common apoptosis pathway by 
inactivating effector caspases (Fulda et al., 2000). ACT-
D and STS require Bax and Bak to induce cytochrome c 
liberation to take the cell to its death. These data indicate 
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that PV patients’ lymphocyte resistance to apoptosis in-
duced by STS and ACT-D may be a consequence of low 
levels of Bax mRNA.
Cytarabine, a cytotoxic antineoplastic agent shows 
cell phase specificity, initially destroying cells that synthe-
size DNA and, under certain conditions, blocking progres-
sion of phase G1 to phase S. The mechanism of action is 
not completely known, but the drug seems to inhibit DNA 
polymerase during replication and damage DNA, thus ac-
tivating the p53 pathway. Other antineoplastic drugs tested 
in this study were etoposide (Vepesid) and teniposide, both 
inhibitors of topoisomerase II; their main effects may be 
related to rupture of DNA double loop by enzyme inter-
action or production of free radicals; the drugs increase 
TRAIL receptor expression and stimulate p53 pathway by 
damaging DNA (Karpinish et al., 2002; Li et al., 2006).
The percentages of cell death detected in PV patients 
suggest mononuclear cells resistance to most drugs and 
indicate that cells may show alterations in at least one 
of the regulatory mechanisms of cellular apoptosis. The 
decreased cell susceptibility to death may be associated 
with cell accumulation in PV, being partially responsible 
for the morbidity/mortality of patients with the disease.
In conclusion, high levels of A1 and Mcl-1 and a 
reduced expression of antiapoptotic Bcl-2 and Bcl-xL 
and proapoptotic Bad and Bax genes in CD34 HSC were 
detected in PV patients. In leukocytes, A1 expression was 
elevated and Bad and Bax mRNA levels were decreased. 
Thus, overexpression of the above antiapoptotic genes and 
a low mRNA level of Bax and Bad proapoptotic molecules 
may be associated with PV pathogenesis.
Additionally, a low expression of Bad and Bax 
proapoptotic genes also seems to be linked to PV lympho-
cyte resistance to apoptosis and contribute to the disease 
physiopathology.
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TABLE S1 - Percentiles 25 and 75 of gene expression 2-∆∆Ct from Bcl-2 family members in hematopoietic stem cells and peripheral 
leukocytes in PV patients and controls
Genes CD34+ HSC Peripheral Leukocytes
Controls
P25 - P75
PV Patients
P25 - P75
Controls
P25 - P75
PV Patients
P25 - P75 
A1 0.3596-4.212 4.068-83.69 0.4918-2.191 4.428-21.17
Bad 0.0003-9.596 0.005-7.556 0.3045-2.407 0.0582-2.053
Bax 0.007-9.659 0.0009-8.017 0.2187-4.631 0.1075-0.4351
Bcl-2 0.3801-2.539 0.0277-0.7124 0.2462-1.969 0.2535-8.265
Bcl-W 0.4549-1.704 0.1067-42.67 0.0118-9.754 0.1846-6.439
Bcl-xL 1.067-3.491 0.5042-1.457 0.6067-1.610 0.5790-4.920
Bid 0.4190-3.681 4.015-26.11 0.2778-3.286 0.3461-3.180
Mcl-1 0.3248-1.044 1.803-12.33 0.7861-1.753 1.071-7.579
HSC: Hematopoietic Stem Cells; PV: Polycythemia Vera; P: Percentile.
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FIGURE S1 - A1, Bcl-xL, Bad, and Bim-EL protein expression determined in peripheral leukocyte lysates from four PV patients 
and four controls. A1, Bcl-xL, Bad, and Bim-EL expression were assessed by immunoblot with specific antibody. Protein loading 
is controlled by beta-actin or tubulin. Results were shown by blotting figures and protein expression quantification detected by 
densitometry and expressed by the ratio of target protein integrated density values (IDV) and beta-actin or tubulin IDV. Bcl-xL and 
A1 presented a high expression while Bad protein levels were decreased in PV patients in comparison with controls. Bim-EL proteic 
levels are also reduced in PV patient leukocytes being only 35% of the values in normal individuals.
TABLE S2 - Correlation between JAK2 V617F allele burden 
and genes expression of Bcl-2 family members in PV patients
Genes CD34+ HSC Peripheral Leukocytes
 r p  r  p
A1 0.1763 p>0.05 -0.03647 p>0.05
Bad -0.3465 p>0.05 -0.09726 p>0.05
Bak -0.3404 p>0.05 -0.08113 p>0.05
Bax -0.2979 p>0.05 -0.03647 p>0.05
Bcl-2 -0.6565 p>0.05 0.1216 p>0.05
Bcl-w -0.1398 p>0.05 0.3536 p>0.05
Bcl-xL -0.2675 p>0.05 0.01824 p>0.05
Bid -0.2614 p>0.05 -0.2349 p>0.05
Bik -0.1094 p>0.05 -0.04863 p>0.05
Bim-EL -0.2675 p>0.05 -0.1702 p>0.05
Bok -0.2371 p>0.05 -0.1885 p>0.05
Mcl-1 0.1216 p>0.05 0.3161 p>0.05
HSC: Hematopoietic stem cell.
